Medtronic's (MDT +0.2%) CoreValve heart implant increased 1-year survival rates amongst patients...

|About: Medtronic plc (MDT)|By:, SA News Editor

Medtronic's (MDT +0.2%) CoreValve heart implant increased 1-year survival rates amongst patients in a study and it improved their quality of life. Separately, a trial of the company's Symplicity renal denervation treatment helped reduce blood pressure in patients with "treatment-resistant hypertension," who have a high risk of "various cardiovascular events."